{"id":"df277","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DF277 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.","oneSentence":"DF277 is a small molecule drug that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:47.918Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT03196973","phase":"PHASE3","title":"Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa","status":"COMPLETED","sponsor":"Salvat","startDate":"2017-07-22","conditions":"Acute Otitis Externa","enrollment":493},{"nctId":"NCT01404611","phase":"PHASE3","title":"Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients","status":"COMPLETED","sponsor":"Salvat","startDate":"2011-06","conditions":"Acute Otitis Media","enrollment":331},{"nctId":"NCT01996748","phase":"PHASE3","title":"Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema","status":"COMPLETED","sponsor":"Salvat","startDate":"2012-02","conditions":"Otic Eczema","enrollment":135},{"nctId":"NCT01395966","phase":"PHASE3","title":"Clinical Study to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Middle Ear Infections in Pediatric Patients","status":"COMPLETED","sponsor":"Salvat","startDate":"2011-06","conditions":"Acute Otitis Media","enrollment":331}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Corticosteroid"],"phase":"phase_3","status":"active","brandName":"DF277","genericName":"DF277","companyName":"Salvat","companyId":"salvat","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DF277 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}